Andromachi Vryonidou
Overview
Explore the profile of Andromachi Vryonidou including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
60
Citations
790
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Vryonidou A, Mizamtsidi M, Palioura E, Kalogeris N, Vassilatou E, Ioannidis D, et al.
Endocrine
. 2025 Jan;
PMID: 39883390
Purpose: Several studies suggest a linkage between PCOS and autoimmunity with a high frequency of chronic autoimmune thyroiditis (AIT) reported in PCOS patients, however, this subject remains controversial. The aim...
2.
Nastos C, Papaconstantinou D, Paspala A, Pararas N, Vryonidou A, Pikouli A, et al.
Langenbecks Arch Surg
. 2024 Oct;
409(1):316.
PMID: 39432022
Purpose: Adrenocortical carcinoma (ACC) poses a significant challenge in healthcare due to its aggressive nature and rarity. Prior reports suggest a poorer prognosis associated with hormone-secreting neoplasms. This study aims...
3.
Papini E, Attanasio R, Zarkovic M, Nagy E, Negro R, Perros P, et al.
Endocrine
. 2024 Aug;
87(1):262-272.
PMID: 39217207
Background: Treatment of simple goiter (SG) growing over time with thyroid hormone (TH) therapy is discouraged by international guidelines. Purpose: To ascertain views of European thyroid specialists about TH treatment...
4.
Theodorou A, Karagiannakis D, Stefanaki K, Kassi E, Peppa M, Vryonidou A, et al.
Hormones (Athens)
. 2024 Jun;
23(4):637-653.
PMID: 38922384
Cardiovascular disease (CVD) is the leading cause of morbidity and mortality worldwide. While it was previously believed that men have greater susceptibility to CVD, recent research suggests that women face...
5.
Negro R, Zarkovic M, Attanasio R, Hegedus L, Nagy E, Papini E, et al.
Clin Endocrinol (Oxf)
. 2024 Jun;
101(2):180-190.
PMID: 38856700
Objectives: The use of levothyroxine (LT4) treatment aiming to improve fertility in euthyroid women with positive thyroid peroxidase antibodies (TPOAb) is not supported by the available evidence. The aim of...
6.
Stefanaki K, Karagiannakis D, Peppa M, Vryonidou A, Kalantaridou S, Goulis D, et al.
Nutrients
. 2024 Apr;
16(7).
PMID: 38613082
Polycystic ovary syndrome (PCOS), the most common endocrine disorder in women of reproductive age, constitutes a metabolic disorder frequently associated with obesity and insulin resistance (IR). Furthermore, women with PCOS...
7.
Strati M, Moustaki M, Psaltopoulou T, Vryonidou A, Paschou S
Endocrine
. 2024 Mar;
85(3):965-978.
PMID: 38472622
The incidence and prevalence of type 2 diabetes mellitus (T2DM) in young individuals (aged <40 years) have significantly increased in recent years, approximating two to threefold increase in the respective...
8.
Attanasio R, Zarkovic M, Papini E, Nagy E, Negro R, Perros P, et al.
Thyroid
. 2024 Feb;
34(4):429-441.
PMID: 38368541
Hypothyroidism is common, however, aspects of its treatment remain controversial. Our survey aimed at documenting treatment choices of European thyroid specialists and exploring how patients' persistent symptoms, clinician demographics, and...
9.
Moustaki M, Markousis-Mavrogenis G, Vryonidou A, Paschou S, Mavrogeni S
Endocrine
. 2023 Dec;
83(3):548-558.
PMID: 38129722
Background: Cushing's Syndrome (CS) is associated with increased cardiovascular morbidity and mortality. In endogenous CS, cardiovascular mortality remains increased for up to 15 years post remission of hypercortisolism. Similarly, patients...
10.
Moustaki M, Kontogeorgi A, Tsangkalova G, Tzoupis H, Makrigiannakis A, Vryonidou A, et al.
Front Reprod Health
. 2023 Sep;
5:1194575.
PMID: 37744287
Premature Ovarian Insufficiency (POI) is a multi-factorial disorder that affects women of reproductive age. The condition is characterized by the loss of ovarian function before the age of 40 years...